Vol 9, No 5 (2008): Practical Diabetology
Research paper
Published online: 2008-10-23
Treatment intensification with insulin analogs in type 2 diabetics
Diabetologia Praktyczna 2008;9(5):209-219.
Abstract
Nowadays we can observe the increasing prevalence
of diabetes all over the world. Despite new hipoglycaemic
drugs implementation, including modern
insulin products the metabolic control of diabetes
does not improve. Generally it results from too late
introducing insulinotherapy or noneffective treatment
intensification. In this paper we present insulin analogues
efficiacy and safety profile in beginning or advancement
in 1492 patients with diabetes type 2. Data
were collected from observative questionnaire research
of two visits with 3 months interval. The mean
time of diabetes duration was 9.77 years. Mean HbA1c
level - 8.86%, fasting blood glucose 160 mg/dl, postprandial
glucose 216 mg/dl. The commonest cause of
treatment intensification was abnormal postprandial
glucose (88.5%), fasting glucose (73.8%) and HbA1c
(38.6%). Modification of insulinotherapy was personalized.
NovoRapid and Insulatard or NovoMix30 in
monotherapy or together with NovoRapid were used.
Treatment change caused decrease of HbA1c level to
7.7%, fasting glycaemia to 123.46 mg/dl and post prandial glucose to 155.32 mg/dl. Differences were
statistically significant. 76.9% of patients considered
the treatmnet more comfortable. Number of hypoglycaemia
was lower. One of the most important factors
influencing the new treatment efficiacy is better
patient compliance depending on time of insulin injection
- immediately before a meal.
Keywords: type 2 diabetesaspart insulininsulin analogues